February 8, 2010 — Bethesda-based Northwest Biotherapeutics, Inc. (OTC Bulletin Board: NWBO), a development stage biotechnology company focused on personalized cancer vaccines to enhance immune system responses to tumors, has retained Market Media Connect as their communications agency of record. Led from its Los Angeles headquarters, Market Media Connect will support Northwest's communication objectives as the company moves into the next phase of its development. "We have spent over a decade developing our technologies and advancing our clinical programs" said Dr. Alton Boynton, Chief Executive Officer of NWBT in a statement. "As we continue our own development, and as immune therapies for cancer come of age, we need a well-established agency with a broad base of expertise to help us communicate effectively about our vaccines, our clinical progress and the underlying scientific support. We are confident Market Media Connect is the right agency partner to help us reach the next level in our communication efforts."

Currently approved cancer treatments are frequently ineffective, cause undesirable toxic side effects and provide limited clinical benefits. In its novel cancer therapies, Northwest Biotherapeutics mobilizes dendritic cells ('DCs'), which are the master cells of the immune system. Northwest Biotherapeutics' lead products are proprietary dendritic cell vaccines for prostate and brain cancer.

"Northwest Biotherapeutics is well positioned to transform the way the biotech community views cancer treatments," said James Morham, CEO of Market Media Connect. "We look forward to working in tandem with Northwest Biotherapeutics to expand and strengthen their external communications and visibility."

Source: Market Media Connect